Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Post time 7 hour(s) ago

journal：New England Journal of Medicine

Authors：Gerald W. Prager; Julien Taieb; Marwan Fakih; Fortunato Ciardiello; Eric Van Cutsem; Elena Elez; Felipe M. Cruz; Lucjan Wyrwicz; Daniil Stroyakovskiy; Zsuzsanna Pápai; Pierre-Guillaume Poureau; Gabor Liposits; Chiara Cremolini; Igor Bondarenko; Dominik P. Modest; Karim A. Benhadji; Nadia Amellal; Catherine Leger; Lock Vidot; Josep Tabernero

Published date：2023-5-4

DOI：10.1056/nejmoa2214963

PDF link：http://www.nejm.org/doi/pdf/10.1056/NEJMoa2214963

Article link：https://doi.org/10.1056/nejmoa2214963

Article Source：Massachusetts Medical Society。

Remark：

Post time 12 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[NEJM] Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[NEJM] Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer